Merck 4Q Revenues: $6 billion (+5%) 4Q Earnings: $473.9 million* (earnings were $1.1 billion 4Q2005) FY Revenues: $22.6 billion (+3%) FY Earnings: $4.4 billion (-4%) Comments: Singulair sales were $960 million for the quarter, up 17% and sales for the year were $3.6 billion, up 20%. Global sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough partnership, reached $1.1 billion for the quarter, up 46% and for the year were $3.9 billion, up 60%. Zocor sales were ...